This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.
EP. 1: Overactive Bladder Prevalence and Impact
Dr Alex Rogers and Dr Scott MacDiarmid discuss overactive bladder (OAB) prevalence and diagnosis and its impact on quality of life.
EP. 2: Overactive Bladder Treatment
Drs MacDiarmid and Rogers discuss treatment for OAB and the use of care pathways to treat patients.
EP. 3: Third-Line Treatments for Overactive Bladder
Overactive bladder experts discuss when they move from one treatment to another, and share pros and cons of available third-line treatments.
EP. 4: Tibial Nerve Stimulation Devices for OAB Treatment
Experts discuss tibial nerve stimulation, an emerging treatment for OAB.
EP. 5: Implantable Tibial Nerve Stimulation: eCoin
Drs Rogers and MacDiarmid discuss data from feasibility and pivotal studies with eCoin, a tibial nerve stimulation device, and how it compares to other third-line treatments.
EP. 6: Reimplantation of Tibial Nerve Stimulation Device (eCoin)
OAB experts share their experience with reimplantation of a tibial nerve stimulation device (eCoin).
EP. 7: Future of Overactive Bladder Treatment
Drs MacDiarmid and Rogers discuss barriers to OAB treatments and therapies on the horizon.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC